KDM1A and hepatocellular carcinoma: KDM1A inhibitors, such as pargyline and GSK2879552, decreased stem-like properties of sorafenib-resistant HCC cells, inhibited β-catenin activity, and resensitized these cells to sorafenib in vivo [82].